Idexx Laboratories Inc. (NASDAQ:IDXX) Chairman Jonathan W. Ayers sold 40,000 shares of the business’s stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $107.85, for a total transaction of $4,314,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Idexx Laboratories Inc. (NASDAQ:IDXX) opened at 109.30 on Tuesday. Idexx Laboratories Inc. has a 52 week low of $63.48 and a 52 week high of $117.84. The company has a 50-day moving average of $110.43 and a 200-day moving average of $101.05. The firm has a market cap of $9.80 billion, a price-to-earnings ratio of 46.55 and a beta of 0.48.

Idexx Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Tuesday, November 1st. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. The business earned $448.30 million during the quarter, compared to analysts’ expectations of $448.60 million. Idexx Laboratories had a net margin of 12.36% and a negative return on equity of 788.91%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $0.48 earnings per share. Equities research analysts forecast that Idexx Laboratories Inc. will post $2.38 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Idexx Laboratories (NASDAQ:IDXX)

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in Idexx Laboratories by 4.0% in the first quarter. Geode Capital Management LLC now owns 576,331 shares of the company’s stock worth $45,138,000 after buying an additional 22,351 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Idexx Laboratories by 242.6% in the first quarter. Renaissance Technologies LLC now owns 437,504 shares of the company’s stock worth $34,265,000 after buying an additional 309,804 shares during the last quarter. Columbus Circle Investors raised its position in Idexx Laboratories by 7.0% in the second quarter. Columbus Circle Investors now owns 816,808 shares of the company’s stock worth $75,849,000 after buying an additional 53,560 shares during the period. Smith Asset Management Group LP acquired a new position in Idexx Laboratories during the second quarter worth $12,467,000. Finally, Welch & Forbes LLC raised its position in Idexx Laboratories by 0.6% in the second quarter. Welch & Forbes LLC now owns 198,190 shares of the company’s stock worth $18,404,000 after buying an additional 1,169 shares during the period. Institutional investors and hedge funds own 91.71% of the company’s stock.

Several research firms have recently weighed in on IDXX. Zacks Investment Research upgraded shares of Idexx Laboratories from a “hold” rating to a “buy” rating and set a $106.00 price objective on the stock in a research note on Monday, July 25th. Canaccord Genuity restated a “buy” rating and set a $120.00 price objective on shares of Idexx Laboratories in a research note on Monday, August 22nd. Stifel Nicolaus restated a “buy” rating and set a $120.00 price objective (up from $92.00) on shares of Idexx Laboratories in a research note on Wednesday, August 3rd. Northcoast Research upgraded shares of Idexx Laboratories from a “sell” rating to a “neutral” rating in a research note on Wednesday, August 3rd. Finally, Bank of America Corp. restated a “neutral” rating on shares of Idexx Laboratories in a research note on Thursday, September 29th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $105.20.

About Idexx Laboratories

5 Day Chart for NASDAQ:IDXX

Receive News & Stock Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related stocks with our FREE daily email newsletter.